Immuno-Oncology

The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.

cancer vaccine | Image credit: IO Biotech
From “Super Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 Results

May 3rd 2025

Round FDA approval stamp in blue ink | Image Credit: © Surendra - stock.adobe.com
FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

March 31st 2025

Travis Osterman, DO, MS, FAMIA, FASCO
Leveraging AI to Optimize Precision Immunotherapy at Vanderbilt

October 25th 2024

Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials
Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials

September 15th 2024

More News

FDA Approves Cilta-cel to Treat R/R Multiple Myeloma
March 1st 2022

FDA Approves Cilta-cel to Treat R/R Multiple Myeloma

Mary Caffrey
FDA approval is based on CARTITUDE-1, a phase 1b/2 trial in which investigators reported that cilta-cel produced an objective response rate (ORR) of 98% and a stringent complete response rate of 78%.
Natural Killer cells
February 26th 2022

With Natural Killer Cell Immunotherapy, Alloreactive Cell Dose May Be Predictive of Response

Rose McNulty
Research has shown that adoptive immunotherapy using natural killer cells may be beneficial in leukemia treatment. The follow-up to a recent study found that the dose of alloreactive natural killer cells matters for treatment response.
Natural killer cell
February 25th 2022

Natural Killer Cell–Based Immunotherapy: A Less Toxic Treatment for Leukemia?

Rose McNulty
A recent review examined natural killer–based therapies, a type of immunotherapy that holds promise for treating leukemia with less toxicity than currently available therapies.
EBO
February 14th 2022

With Approval for Axi-cel in Second-line on the Horizon, CAR T-Cell Therapy Poised to Enter New Phase

Mary Caffrey
Lessons from the early days of chimeric antigen receptor (CAR) T-cell therapy remain fresh as Kite Pharma prepares for the FDA to act on its supplemental biologics license application for use of axi-cel as second-line therapy in relapsed or refractory large B-cell lymphoma. A target action date is set for April 1, 2022.
Steven Pergam, MD, MPH, Discusses NCCN’s “Strong Preference” for mRNA Vaccines in Patients With Cancer to Prevent COVID-19
February 13th 2022

Steven Pergam, MD, MPH, Discusses NCCN’s “Strong Preference” for mRNA Vaccines in Patients With Cancer to Prevent COVID-19

Mary Caffrey
A statement from NCCN’s Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis said that the panel “endorses vaccination for all eligible persons based on FDA-approved indications or emergency use authorization” and emphasized the need for everyone to be fully vaccinated—including third doses.
medical researcher
February 12th 2022

Trials for Cancer Immunotherapies Grow Significantly From 2017 to 2021

Laura Joszt, MA
While the number of trials for cancer immunotherapies grew significantly, combination therapies being studied increased while monotherapies decreased.
IO-TKI Combinations Have Potential as Preferred First-line mRCC Therapy
February 12th 2022

IO-TKI Combinations Have Potential as Preferred First-line mRCC Therapy

Rose McNulty
Metastatic renal cell carcinoma (mRCC) has seen increased treatment options in recent years, including immunotherapy (IO) combinations paired with tyrosine kinase inhibitors (TKI). A meta-analysis of phase 3 trials aimed to compare and rank available first-line treatments.
Sunil Verma, MD
February 5th 2022

Dr Sunil Verma on Benefits, Safety Findings in HIMALAYA Trial

Mary Caffrey Hayden E. Klein
Sunil Verma, MD, senior vice president and global head of oncology, medical at AstraZeneca, summarizes the benefits and safety findings discovered in the HIMALAYA study.
liver image
February 3rd 2022

Study Assesses Real-world Outcomes of Immunotherapy in Patients With HCC, Comorbidities

Rose McNulty
A poster presentation from the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium suggests more research is needed to confirm the optimal treatment algorithms for patients with hepatocellular carcinoma.
doctor with patient in bed
January 29th 2022

Presence of NAFLD Cirrhosis Impacts Best Response to Immunotherapy in Patients With HCC

Laura Joszt, MA
Disease progression was more likely to be the best response to immunotherapy for patients with hepatocellular carcinoma (HCC) and cirrhosis due to nonalcoholic fatty liver disease (NAFLD).
Sunil Verma, MD
January 29th 2022

Dr Sunil Verma Discusses Design of HIMALAYA Trial

Mary Caffrey Hayden E. Klein
Sunil Verma, MD, senior vice president and global head of oncology, medical at AstraZeneca, explains the design of the HIMALAYA study, including the dosing strategy used.
Phase 3 Data for Pembrolizumab in Hepatocellular Carcinoma Show Significant Improvements in OS, PFS
January 18th 2022

Phase 3 Data for Pembrolizumab in Hepatocellular Carcinoma Show Significant Improvements in OS, PFS

Mary Caffrey
Merck had previously received accelerated approval for pembrolizumab for patients with advanced hepatocellular carcinoma (HCC); an FDA panel left the approval in place while waiting on results from KEYNOTE-394.
CYNK-101 Receives Fast Track Designation for HER2-Positive Gastric/GEJ Cancers
January 18th 2022

CYNK-101 Receives Fast Track Designation for HER2-Positive Gastric/GEJ Cancers

AJMC Staff
Natural killer cell therapy CYNK-101 was granted fast track designation by the FDA to treat HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with standard chemotherapy, trastuzumab, and pembrolizumab.
Blue Ridge Cancer Care’s Goldschmidt Presents Data on Managing Hematological Events
January 9th 2022

Blue Ridge Cancer Care’s Goldschmidt Presents Data on Managing Hematological Events

Mary Caffrey
Studies have shown that administering trilaciclib prior to chemotherapy can reduce myelosuppression and improve health-related quality of life. Jerome Goldschmidt, MD, said future studies will look at how it interacts with immunotherapy.
Steven Pergam, MD, MPH
January 9th 2022

Dr Steven Pergam Describes Evolving COVID-19 Recommendations for Cancer Community

Mary Caffrey Hayden E. Klein
Steven Pergam, MD, MPH, director of infection prevention at Seattle Cancer Care Alliance and infectious disease physician at Fred Hutchinson Cancer Research Center, describes the shifts in COVID-19 recommendations for patients with cancer and those receiving CAR T-cell therapy.
Steven Pergam, MD, MPH
January 5th 2022

Dr Steven Pergam Explains NCCN COVID-19 Update

Mary Caffrey Hayden E. Klein
Steven Pergam, MD, MPH, director of infection prevention at Seattle Cancer Care Alliance and infectious disease physician at Fred Hutchinson Cancer Research Center, explains the National Comprehensive Cancer Network (NCCN) update on COVID-19 vaccines and prevention.
NCCN Update on COVID-19 Prevention Gives “Strong Preference” for mRNA Vaccines in Patients With Cancer
January 4th 2022

NCCN Update on COVID-19 Prevention Gives “Strong Preference” for mRNA Vaccines in Patients With Cancer

Mary Caffrey
The update recommends that patients who receive CAR T-cell therapy wait 3 months before getting a COVID-19 vaccine.
Phase 1 Study in R/R Hodgkin Lymphoma Shows Significant Responses to Pembrolizumab Plus Oral Vorinostat
January 4th 2022

Phase 1 Study in R/R Hodgkin Lymphoma Shows Significant Responses to Pembrolizumab Plus Oral Vorinostat

In preclinical studies, HDAC inhibitors have been shown to have immunomodulatory effects— including enhancing antigen presentation, recruiting T cells into tumors, and promoting T-cell function—when combined with PD-1 inhibitors.
ACCC Presents Survey Responses on Adoption of Bispecific Antibodies
January 2nd 2022

ACCC Presents Survey Responses on Adoption of Bispecific Antibodies

AJMC Staff
ACCC created a survey to better understand multidisciplinary cancer providers’ experiences with bispecific antibodies, with a focus on experiences with blinatumomab. Results of the survey were presented in an abstract during the 2021 American Society of Hematology Annual Meeting & Exposition.
Top 5 Most-Read Articles From Evidence-Based Oncology™ for 2021
December 28th 2021

Top 5 Most-Read Articles From Evidence-Based Oncology™ for 2021

Mary Caffrey
Articles on advances in immuno-oncology and non-small cell lung cancer were popular with readers in the past year.
Tharaldson
December 20th 2021

CONFERENCE COVERAGE: AMCP Nexus 2021

Skylar Jeremias
Coverage from the Academy of Managed Care Pharmacy Nexus 2021 meeting, held in Denver, Colorado.
OneOncology Speakers Make Case for Community Setting in Research, Value Delivery
December 20th 2021

OneOncology Speakers Make Case for Community Setting in Research, Value Delivery

Mary Caffrey
Duncan Allen, MHA, introduced the audience to the OneR clinical research initiative, and Jeffrey Patton, MD, discussed how the hospital transparency law has bolstered the case for the value of community oncology.
Immuno-oncology graphic
September 4th 2021

Murine Study Suggests Novel I-O Combo May Be Effective in CRC

Jaime Rosenberg
The murine study, which assessed the combination of foretinib and an anti–PD-1 antibody, found that the regimen enhanced antitumor activity, offering promise in a cancer that has seen less success with immunotherapies than others.
Immunotherapy graphic
August 31st 2021

Study Will Collect Patient Preferences for NSCLC Treatments

Jaime Rosenberg
This study protocol comes amid a paradigm shift in the treatment of advanced-stagen non–small cell lung cancer (NSCLC) following the emergence and uptake of immunotherapy.
Doctor providing immunotherapy education to patient
August 25th 2021

Improved Immunotherapy Education Needed for Patients to Grasp Benefits, Risks

Jaime Rosenberg
Survey responses from patients with advanced cancer revealed that there were gaps in knowledge across various aspects of immunotherapy treatment, including about side effects and curative potential.
molecule graphic
August 23rd 2021

Meta-Analysis Highlights Promising Efficacy, Safety of Approved CAR T-Cell Products

Jaime Rosenberg
Researchers found the 3 treatments—axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel (liso-cel)—showed promising efficacy and safety results across histological types, although they noted a need for more real-world data to validate the efficacy of liso-cel.
Charts and data
August 22nd 2021

Analysis Offers Longer-Term Safety Profile of CAR T-Cell Therapy for B-ALL

Jaime Rosenberg
The findings come from a pooled analysis of the ELIANA and ENSIGN trials, both of which led to the approval of tisagenlecleucel for these patients.
August 2021: Targeted Therapy & Immuno-Oncology
August 17th 2021

August 2021: Targeted Therapy & Immuno-Oncology

Laura Joszt, MA Jaime Rosenberg
Oncology Value Coalition
August 17th 2021

Cardinal Health Experts Outline How Research, Regulatory Approaches Can Speed Drug Approval

Mary Caffrey
Impact of COVID-19 on Disparities in Cancer Outcome Spans Various Groups of Patients
August 13th 2021

Impact of COVID-19 on Disparities in Cancer Outcome Spans Various Groups of Patients

Jaime Rosenberg
Recent research showed that patients with Medicaid are more likely than commercially insured patients to have worsened end-of-life experience and that Black patients with breast cancer fare worse than other ethnic groups when it comes COVID-19 outcomes.
<1
...
34567891011
...
15>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo